Skip to main content
Search
Newsletters
Watchlist
Home
Watchlist
For You
Canada
World
Business
Investing
Personal Finance
Opinion
Politics
Sports
Life
Arts
Drive
Real Estate
Latest in
TSX Today:
ENB-T
+1.86%
SU-T
+1.89%
LUN-T
-1.51%
CVE-T
+0.78%
K-T
-0.27%
ABX-T
-0.3%
MFC-T
+0.91%
Search stocks, ETFs and Commodities
Instrument Name
Deciphera Pharmaceuticals Inc
Instrument Symbol
(DCPH-Q)
Instrument Exchange
NASDAQ
Add to Watchlist
Create Alerts
USD
Today's Change
Real-Time
Last Update
Last Sale
Cboe BZX Real-Time
USD
After Hours
Change
After Hours
Last Update
After Hours
Price
Volume
Summary
Charts
Profile
Financials
Statistics
Dividends
Price History
Analyst Estimates
Insiders
Deciphera Pharmaceuticals Inc
200 SMITH STREET
Waltham MA 02451 USA
P:
781-209-6400
F:
785-830-2150
http://www.deciphera.com
Sectors & Indices
Sector
Industry
Employees
SIC-2834 Pharmaceutical Preparations
Medical - Biomedical
Indices Russell 2000
Indices Russell 3000
Indices Nasdaq Composite
Profile
Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform.
Key Executives
Name
Title
Thomas P. Kelly
CFO/Chief Accounting Officer/Executive VP/Treasurer
Steven L. Hoerter
CEO/Director/President
Matthew L. Sherman
Chief Medical Officer/Executive VP
Daniel C. Martin
Other Executive Officer/Senior VP
Dashyant Dhanak
Chief Scientific Officer/Executive VP
Jama Pitman
Senior VP, Divisional
More from The Globe
investor newsletter
A look at how people are using the best all-around investing product. Plus, top stock picks from our new Readers’ Portfolio
Yesterday
The close: Month-end repositioning spurs late-day stock rally
Yesterday
Why this money manager thinks investors should get off the sidelines but still be defensive
June 23, 2023
globe advisor weekly newsletter
Canadian investors are ‘underserved’ in alternative investments and private capital
November 25, 2022
Why rising interest in traditional fixed income is not affecting alternatives
September 20, 2022
Fund houses buy up ‘alts’ specialists to move beyond equities and bonds
March 28, 2022
opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza
July 6, 2021
Four ways to create more diversified and resilient portfolios
May 25, 2020